Recalled baby products still on Nevada shelves, officials warn
Gerber Products Company issued a recall for all batches of its Soothe N Chew Teething Sticks on Jan. 31 after reports of choking incidents involving babies and young children. Despite the recall, the U.S. Food and Drug Administration (FDA) confirmed this week that some retailers and online sellers are still offering the product for sale.
On Friday, state and local inspectors launched visits to more than 90 grocery and discount stores across Nevada, working to remove the recalled products.
'When inspectors find the product in a store we will ask the operator to remove them from the shelves voluntarily,' Mark Ports, a state environmental health supervisor, said. 'Otherwise, our staff will place a legal hold on the product and remove it from the shelves.'
Parents who have purchased any of the Soothe N Chew® Teething Sticks products are urged not to feed them to their children and can return them to the retailer for a full refund.
For more information about the recall, visit the Food and Drug Administration.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
13 minutes ago
- CNBC
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
Shares of Novo Nordisk climbed almost 5% Monday after the company's blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease. The company on Friday said that it was granted approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, in combination with a reduced calorie diet and increased physical activity. Novo Nordisk shares were up 5.46% by 10:43 a.m. London time (5:43 a.m. E.T.). The approval makes Wegovy the first GLP-1 class treatment to be authorized for MASH, a progressive liver condition that affects an estimated 5% of U.S. adults, according to the American Liver Foundation. It also advances the drug's applications beyond diabetes and obesity treatment and develops its presence in the metabolic disease market. The approval follows a series of studies indicating the drug's efficacy in reducing the risk of heart attack, stroke and death from cardiovascular causes. "Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide," Martin Holst Lange, Novo Nordisk executive vice president, chief scientific officer and head of research and development, said in a statement. The accelerated approval was based on the first phase of the ESSENCE trial, in which Novo Nordisk said Wegovy demonstrated "a statistically significant and superior improvement" in liver fibrosis compared to placebo. Under the study, the company said almost two-thirds (62.9%) of people treated with Wegovy achieved the resolution of steatohepatitis with no worsening of liver fibrosis, compared to 34.3% who were administered a placebo. More than one-third (36.8%) of those treated with Wegovy achieved improvement in liver fibrosis with no worsening of steatohepatitis after 72 weeks, compared to 22.4% who received a placebo. The second phase of the study is expected in 2029. Novo Nordisk said Friday that Wegovy would be immediately available in the U.S. for MASH. The only other MASH treatment currently approved by the FDA is Madrigal Pharmaceuticals' Rezdiffra, which was cleared in 2024.
Associated Press
3 hours ago
- Associated Press
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-derived medicinal products. This MOU formalizes and deepens a relationship that began in 2015, when GC Biopharma supported TRCS to establish a plasma fractionation facility in Thailand, and reflects the ongoing strategic collaboration between the two parties. Under the terms of the MOU, GC Biopharma and TRCS will jointly develop and operate on-site training and exchange programs for local production personnel. These programs aim to transfer GC Biopharma's advanced manufacturing technologies and expertise to support the development of local capabilities. In addition, both parties intend to continue identifying and expanding collaborative opportunities that align with their respective strengths and interests. The scope of cooperation will be gradually broadened to include potential joint projects such as the transfer of new processing technologies for plasma by-products and other strategic projects. 'This MOU is a significant step in broadening the reach of GC Biopharma's advanced technology and production standards across Asia,' said Hyoungjun Park, Vice President of GC Biopharma. 'Through our collaboration with the TRCS, we aim to achieve mutual growth while contributing to the public good.' 'Enhancing our personnel's capabilities through specialized training and direct knowledge transfer from GC Biopharma is essential to maintaining the quality, safety, and continuity of plasma-derived medicinal products production in Thailand,' said Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre, TRCS. 'This collaboration not only supports the human resource development but also represents an important step for technology transfer and playing a vital role in strengthening the country's pharmaceutical and public health security.' Meanwhile, GC Biopharma continues to expand its global plasma-derived therapeutics business. In addition to entering the U.S. immunoglobulin market in 2024, the company is actively building partnerships in Southeast Asia, where domestic fractionation capabilities remain limited. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kim [email protected] Yelin Jun [email protected] Yoonjae Na [email protected] View original content to download multimedia: SOURCE GC Biopharma
Business Wire
3 days ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
